AmirAli Talasaz is a co-founder of Guardant Health and served as Chairperson of the Board, President and Chief Operating Officer from January 2013 until August 2021. On August 5, 2021, the Company appointed Dr. Talasaz as Co-CEO; on the same day he resigned as Chairperson of the Board and as President and COO.
Prior to co-founding Guardant Health, Dr. Talasaz held various positions at Illumina, Inc., including Senior Director of Diagnostics Research from October 2011 to June 2012, where he led the efforts for emerging clinical applications of next-generation genomic analysis and developed genomic technologies suitable for clinical applications. In March 2008, he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management; the technology was acquired by Illumina in 2009.
During his academic years, he led the Technology Development group at the Stanford Genome Technology Center. He received his Ph.D. in electrical engineering, M.S. in electrical engineering and M.S. in management science and engineering from Stanford University.